Mediterr J Rheumatol 2024;35(Suppl 1):58-62
Anakinra for Refractory Pseudogout in Patients with End-stage Renal Disease on Haemodialysis
Authors Information

1First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece

2“AKESIOS” Dialysis Centre, Alexandroupolis, Greece

3Department of Nephrology, University Hospital of Alexandroupolis Democritus University of Thrace, Alexandroupolis, Greece

C Antoniadou, N Fytanidis, C Papagoras


Calcium pyrophosphate deposition (CPPD) arthritis is the second most common type of crystal-induced arthritis after gout. Acute flares are commonly treated with non-steroidal anti-inflammatory drugs, intra-articular or short-term systemic glucocorticoids or colchicine. However, since there is no pharmacological treatment to reduce CPPD crystal burden, relapsing or chronic CPPD arthritis may be challenging to treat, particularly in patients with end-stage renal disease who are at risk for toxicity of the above medications. Since IL-1β appears to be driving CPPD arthritis, we treated two patients with chronic CPPD arthritis and end-stage renal disease on haemodialysis with the IL-1β receptor antagonist anakinra. In both patients, arthritis resolved quickly, while continuation of anakinra maintained remission and allowed complete glucocorticoid withdrawal. Therefore, anakinra may be a safe and effective option both for short and long-term treatment of CPPD arthritis in patients on chronic renal replacement therapy.

Cite this article as: Antoniadou C, Fytanidis N, Devetzis V, Kantartzi K, Papagoras C. Anakinra for Refractory Pseudogout in Patients with End-stage Renal Disease on Haemodialysis. Mediterr J Rheumatol 2024;35(Suppl 1):58-62.


Article Submitted: 26 Nov 2023; Revised Form: 08 Dec 2023; Article Accepted: 11 Dec 2023; Available Online: 30 Mar 2024

This work is licensed under a Creative Commons Attribution 4.0 International License.

©2024 The Author(s).